S W Chou

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. pmc Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice
    Mark N Prichard
    Department of Pediatrics, University of Alabama School of Medicine, Birmingham, AL, USA
    Virol J 3:18. 2006
  2. pmc Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA
    Antimicrob Agents Chemother 57:3375-9. 2013
  3. pmc Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University, Portland, OR 97239, USA
    Antiviral Res 95:88-92. 2012
  4. pmc Analysis of the human cytomegalovirus genomic region from UL146 through UL147A reveals sequence hypervariability, genotypic stability, and overlapping transcripts
    Nell S Lurain
    Department of Immunology Microbiology, Rush University Medical Center, Chicago, IL, USA
    Virol J 3:4. 2006
  5. pmc Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
    Rachel B Gill
    Department of Pediatrics, University of Alabama School of Medicine, Birmingham, AL, USA
    Virol J 6:9. 2009
  6. pmc Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University and Department of Veterans Affairs Medical Center, Portland, OR 97239, USA
    J Clin Virol 50:287-91. 2011
  7. pmc Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene
    Sunwen Chou
    Medical and Research Services, VA Medical Center and Oregon Health and Science University, P3ID 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, USA
    Antimicrob Agents Chemother 49:2710-5. 2005
  8. pmc Effect of cell culture conditions on the anticytomegalovirus activity of maribavir
    Sunwen Chou
    Medical and Research Services, VA Medical Center and Oregon Health and Scince University, Portland, OR 97239, USA
    Antimicrob Agents Chemother 50:2557-9. 2006
  9. ncbi request reprint Cytomegalovirus UL97 kinase mutations that confer maribavir resistance
    Sunwen Chou
    Oregon Health and Science University and Veterans Affairs Medical Center, Portland, OR, 97239, USA
    J Infect Dis 196:91-4. 2007
  10. pmc Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens
    Sunwen Chou
    Divisionof Infectious Disease, Oregon Health Science University, VA Medical Center, Portland, OR 97239, USA
    Antimicrob Agents Chemother 51:4160-2. 2007

Research Grants

Collaborators

Detail Information

Publications47

  1. pmc Human cytomegalovirus UL27 is not required for viral replication in human tissue implanted in SCID mice
    Mark N Prichard
    Department of Pediatrics, University of Alabama School of Medicine, Birmingham, AL, USA
    Virol J 3:18. 2006
    ..These data are consistent with minimal defects observed in cell culture, but are not consistent with an important role for UL27 in vivo. We conclude that UL27 is not required for viral replication in vivo...
  2. pmc Cytomegalovirus UL97 kinase catalytic domain mutations that confer multidrug resistance
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA
    Antimicrob Agents Chemother 57:3375-9. 2013
    ..Current diagnostic genotyping assays are unlikely to detect F342S and V356G, and the frequency of their appearance in clinical specimens remains undefined...
  3. pmc Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University, Portland, OR 97239, USA
    Antiviral Res 95:88-92. 2012
    ..There is a potential for increased maribavir resistance in UL27-UL97 double mutants...
  4. pmc Analysis of the human cytomegalovirus genomic region from UL146 through UL147A reveals sequence hypervariability, genotypic stability, and overlapping transcripts
    Nell S Lurain
    Department of Immunology Microbiology, Rush University Medical Center, Chicago, IL, USA
    Virol J 3:4. 2006
    ..UL146 and UL147, which encode CXC chemokine homologues are among these variable ORFs...
  5. pmc Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir
    Rachel B Gill
    Department of Pediatrics, University of Alabama School of Medicine, Birmingham, AL, USA
    Virol J 6:9. 2009
    ..Mutation of the amino terminal motif, which is involved in the inactivation of Rb, also renders the virus hypersensitive to the drug and suggests that the motif may play a role in its mechanism of action...
  6. pmc Phenotypic diversity of cytomegalovirus DNA polymerase gene variants observed after antiviral therapy
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University and Department of Veterans Affairs Medical Center, Portland, OR 97239, USA
    J Clin Virol 50:287-91. 2011
    ..Cytomegalovirus UL54 DNA polymerase mutations observed in clinical specimens are of diagnostic significance if confirmed to affect antiviral drug susceptibility...
  7. pmc Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene
    Sunwen Chou
    Medical and Research Services, VA Medical Center and Oregon Health and Science University, P3ID 3710 SW US Veterans Hospital Road, Portland, Oregon 97239, USA
    Antimicrob Agents Chemother 49:2710-5. 2005
    ..Transfer into strain T2211 facilitates the phenotyping of newly observed mutations, combinations of mutations, and clinical CMV sequences without an accompanying viral isolate...
  8. pmc Effect of cell culture conditions on the anticytomegalovirus activity of maribavir
    Sunwen Chou
    Medical and Research Services, VA Medical Center and Oregon Health and Scince University, Portland, OR 97239, USA
    Antimicrob Agents Chemother 50:2557-9. 2006
    ..These effects influence the phenotypic assay of drug susceptibility and suggest the possibility of therapeutically useful combinations of maribavir and cellular kinase inhibitors...
  9. ncbi request reprint Cytomegalovirus UL97 kinase mutations that confer maribavir resistance
    Sunwen Chou
    Oregon Health and Science University and Veterans Affairs Medical Center, Portland, OR, 97239, USA
    J Infect Dis 196:91-4. 2007
    ..The 3 UL97 mutations now known to confer MBV resistance are located upstream of UL97 mutations linked to ganciclovir resistance, closer to kinase domains that are associated with adenosine triphosphate binding and phosphotransfer...
  10. pmc Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens
    Sunwen Chou
    Divisionof Infectious Disease, Oregon Health Science University, VA Medical Center, Portland, OR 97239, USA
    Antimicrob Agents Chemother 51:4160-2. 2007
    ..Bacterial artificial chromosome CMV clones containing pol mutation L845P were nonviable unless repaired with the wild-type sequence...
  11. pmc Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant
    Sunwen Chou
    VA Medical Center P3ID, 3710 SW U S Veterans Hospital Road, Portland, OR 97239, USA
    J Virol 82:246-53. 2008
    ..The existence of viable pol D413A mutants may facilitate the selection of additional drug resistance mutations in vivo and the study of these mutations in vitro...
  12. doi request reprint Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA
    Rev Med Virol 18:233-46. 2008
    ..So far, no UL97 mutations are known to confer resistance to both GCV and MBV...
  13. pmc Cyclopropavir susceptibility of cytomegalovirus DNA polymerase mutants selected after antiviral drug exposure
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA
    Antimicrob Agents Chemother 56:197-201. 2012
    ..Unlike GCV and CDV, exonuclease mutations are not a preferred mechanism of CPV resistance, but mutations in and near pol region III may confer CPV resistance by affecting its recognition as an incoming base for DNA polymerization...
  14. pmc Contrasting drug resistance phenotypes resulting from cytomegalovirus DNA polymerase mutations at the same exonuclease locus
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University, VA Medical Center, Portland, OR 97239, United States
    J Clin Virol 43:107-9. 2008
    ..The levels of resistance conferred by specific mutations are variable, ranging from insignificant resistance to triple-drug resistance...
  15. pmc Diverse cytomegalovirus UL27 mutations adapt to loss of viral UL97 kinase activity under maribavir
    Sunwen Chou
    Department of Veterans Affairs Medical Center, Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon, USA
    Antimicrob Agents Chemother 53:81-5. 2009
    ..Although the function of UL27 is unknown, it does not appear to be a direct antiviral target for MBV...
  16. pmc Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University, and Department of Veterans Affairs Medical Center, Portland, Oregon, USA
    Antimicrob Agents Chemother 54:2371-8. 2010
    ..This information should improve the interpretation of genotypic data generated by diagnostic laboratories...
  17. doi request reprint Recombinant phenotyping of cytomegalovirus sequence variants detected after 200 or 100 days of valganciclovir prophylaxis
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, USA
    Transplantation 90:1409-13. 2010
    ..Recombinant phenotyping was performed to determine whether the previously uncharacterized genotypic changes affected ganciclovir susceptibility, especially in those receiving the longer duration of prophylaxis...
  18. pmc Cytomegalovirus UL97 mutations affecting cyclopropavir and ganciclovir susceptibility
    Sunwen Chou
    Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, USA
    Antimicrob Agents Chemother 55:382-4. 2011
    ..Uncommon mutations M460T and C603R increased cyclopropavir EC(50)s by 8- to 10-fold...
  19. pmc Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir
    Sunwen Chou
    Medical and Research Services, VA Medical Center and Oregon Health and Science University, Portland, USA
    J Virol 78:7124-30. 2004
    ..The UL27 sequence was well conserved in a sample of 16 diverse clinical isolates. Mutation in UL27, a betaherpesvirus-specific early gene of unknown biological function, may adapt the virus for growth in the absence of UL97 activity...
  20. ncbi request reprint A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance
    S Chou
    VA Medical Center P3ID, Portland, OR 97201, USA
    J Infect Dis 182:1765-8. 2000
    ..A single mutation in region V of CMV pol can, therefore, confer multiple drug resistance in a clinical isolate...
  21. ncbi request reprint Cytomegalovirus UL97 phosphotransferase mutations that affect susceptibility to ganciclovir
    Sunwen Chou
    Medical and Research Services, VA Medical Center, Portland, OR 97201, USA
    J Infect Dis 185:162-9. 2002
    ..Low drug levels resulting from oral GCV therapy may predispose the virus to the initial selection of these low-grade UL97 resistance mutations and to later accumulation of other mutations and greater resistance...
  22. ncbi request reprint Antiviral drug resistance in human cytomegalovirus
    S Chou
    Medical and Research Services, VA Medical Center, Portland, Oregon 97201, USA
    Transpl Infect Dis 1:105-14. 1999
    ..This information may help in the selection of alternative therapy...
  23. pmc A nine-codon deletion mutation in the cytomegalovirus UL97 phosphotransferase gene confers resistance to ganciclovir
    S Chou
    Medical and Research Services, Veterans Affairs Medical Center, Portland, Oregon 97201, USA
    Antimicrob Agents Chemother 44:183-5. 2000
    ..The recombinant virus was resistant to ganciclovir (8.4-fold increase in the 50% inhibitory concentration), was sensitive to foscarnet, and replicated normally in cell culture...
  24. ncbi request reprint Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus
    Sunwen Chou
    Medical and Research Services, Veterans Affairs Medical Center, and Division of Infectious Diseases, Oregon Health and Science University, Portland, Oregon 97201, USA
    J Infect Dis 188:32-9. 2003
    ..This study significantly increases the number of confirmed CMV pol resistance mutations, at both conserved and nonconserved loci, with implications for molecular mechanisms and the genotypic diagnosis of antiviral resistance...
  25. pmc Interstrain variation in the human cytomegalovirus DNA polymerase sequence and its effect on genotypic diagnosis of antiviral drug resistance. Adult AIDS Clinical Trials Group CMV Laboratories
    S Chou
    VA Medical Center, Portland, Oregon 97201, USA
    Antimicrob Agents Chemother 43:1500-2. 1999
    ..Sequence alignments showed >98% interstrain homology and amino acid variation in only 4% of the 1, 237 codons. Almost all variation occurred outside of conserved functional domains where resistance mutations have been identified...
  26. ncbi request reprint Mutation in region III of the DNA polymerase gene conferring foscarnet resistance in cytomegalovirus isolates from 3 subjects receiving prolonged antiviral therapy
    S Chou
    Medical and Research Services, VA Medical Center, Portland, Oregon 97201, USA
    J Infect Dis 178:526-30. 1998
    ..6-fold increased ganciclovir resistance. Occurrence of the V809 mutation in 3 unrelated cases suggests that it is a clinically significant viral genetic marker for foscarnet resistance and decreased susceptibility to ganciclovir...
  27. pmc Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus
    Sunwen Chou
    Medical and Research Services, VA Medical Center, Oregon Health and Science University, Portland, OR 97239, USA
    Antimicrob Agents Chemother 50:3470-2. 2006
    ..Antiviral activities of foscarnet and cidofovir were unaffected by maribavir...
  28. ncbi request reprint Cytomegalovirus drug resistance and clinical implications
    S W Chou
    Infectious Disease Section, VA Medical Center, Portland, Oregon 97201, USA
    Transpl Infect Dis 3:20-4. 2001
    ..The emergence of drug resistance may be reduced by optimization of host immunity, use of potent antiviral drug regimens, and adherence to dosing regimens that adequately suppress viral replication...
  29. ncbi request reprint Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin
    D V Gopal
    Divisions of Gastroenterology and Hepatology, Oregon Health Sciences Center and Portland Veteran Affairs Medical Center, 37 SW US Veterans Hospital Rd, Portland, OR 97201, USA
    Liver Transpl 7:181-90. 2001
    ..Multicenter trials using combination therapy to identify factors predictive of response are needed in the subset of patients with progressive allograft injury...
  30. ncbi request reprint Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection
    Melissa D Murphy
    Medical and Research Services, Portland VA Medical Center, Oregon 97201, USA
    Dig Dis Sci 47:1195-205. 2002
    ..However, the finding of greater variability among treatment responders in the carboxy end of NS5A suggests that the V3 region merits further investigation...
  31. ncbi request reprint HIV protease mutations associated with amprenavir resistance during salvage therapy: importance of I54M
    Melissa D Murphy
    Medical and Research Services, VA Medical Center P3ID, 3710 SW US Veterans Hospital Road, Portland, OR 97239, USA
    J Clin Virol 30:62-7. 2004
    ..To examine the clinical significance of HIV protease mutations detected before and after therapy with amprenavir...
  32. ncbi request reprint Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis
    Adriana Weinberg
    University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Infect Dis 187:777-84. 2003
    ..016). The incidence of foscarnet resistance after 6, 9, and 12 months of therapy was 13%, 24%, and 37%, respectively...
  33. doi request reprint Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation
    Michael Y Shapira
    Hadassah Hebrew University Medical Center, Jerusalem, Israel
    Clin Infect Dis 46:1455-7. 2008
    ..Artesunate treatment resulted in a 1.7-2.1-log reduction in viral load by treatment day 7, with a viral half-life of 0.9-1.9 days, indicating a highly effective block in viral replication...
  34. pmc How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients
    Kathryn L Springer
    Division of Infectious Diseases, University of Colorado Health Sciences Center, 4200 E 9th Ave, C 227, Denver, CO 80220, USA
    J Clin Microbiol 43:208-13. 2005
    ..Novel antivirals or combination therapy may be required for the treatment of drug-resistant CMV in HCT recipients and perhaps in other severely immunocompromised patients...
  35. ncbi request reprint Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet
    W Lawrence Drew
    UCSF Mount Zion Medical Center, University of California, 1600 Divisadero Street, San Francisco, CA 94115, USA
    J Clin Virol 37:124-7. 2006
    ..The cytomegalovirus (CMV) UL97 inhibitor drug maribavir (MBV) is undergoing clinical antiviral trials...
  36. ncbi request reprint Absence of activation of CMV by blood transfusion to HIV-infected, CMV-seropositive patients
    W Lawrence Drew
    University of California, San Francisco, Mount Zion Medical Center, California 94115, USA
    Transfusion 43:1351-7. 2003
    ....
  37. pmc Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates
    Gillian M Scott
    Virology Research, POWH and UNSW Research Laboratories, Level 3 Clinical Sciences Building, Prince of Wales Hospital, Avoca Street, Randwick, NSW 2031, Australia
    Antimicrob Agents Chemother 51:89-94. 2007
    ..The additive effect of multiple mutations on antiviral susceptibility suggests that increasing antiviral-resistant phenotypes can result from different virus-antiviral interactions...
  38. ncbi request reprint Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients
    Jennifer E Marfori
    Medical and Research Services, VA Medical Center and Oregon Health and Science University, Portland, OR, USA
    J Clin Virol 38:120-5. 2007
    ..We report on two allogeneic stem cell transplant recipients who developed cytomegalovirus disease associated with new viral mutations that conferred antiviral drug resistance...
  39. pmc Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication
    Laura Hertel
    Department of Microbiology and Immunology, University of Western Ontario, London, Ontario, Canada
    PLoS Pathog 3:e6. 2007
    ..Thus, Cdk1 is necessary and sufficient to drive pseudomitosis, whereas a combination of viral and cell cycle-regulated kinases is important during viral replication...
  40. ncbi request reprint Reconstitution of hepatitis C virus-specific T-cellmediated immunity after liver transplantation
    Scott J Weston
    Department of Medicine, Oregon Health and Science University, USA
    Hepatology 41:72-81. 2005
    ..Supplementary material for this article can be found on the HEPATOLOGY website (http://interscience. wiley.com/jpages/0270-9139/suppmat/index.html)...
  41. ncbi request reprint Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine
    Melissa D Murphy
    Infectious Disease Section, Veterans Affairs Medical Center, and Oregon Health and Science University, Portland, Oregon 97201, USA
    Clin Infect Dis 36:1082-5. 2003
    ....
  42. ncbi request reprint Tumor necrosis factor-alpha promoter polymorphisms and the risk of rejection after liver transplantation: a case control analysis of 210 donor-recipient pairs
    Saad F Jazrawi
    Liver Transplantation Program, the Division of Gastroenterology Hepatology, Portland Veterans Administration Medical Center, OR 97207, USA
    Liver Transpl 9:377-82. 2003
    ..In this large case control analysis of patients undergoing liver transplantation for diverse etiologies, TNF promoter polymorphisms were not independently associated with rejection or survival...
  43. pmc Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments
    Thomas D Wu
    Department of Biochemistry, Stanford University, Stanford, California 94305, USA
    J Virol 77:4836-47. 2003
    ..The presence of mutational clusters provides insight into the complex mutational patterns required for HIV-1 protease inhibitor resistance...
  44. ncbi request reprint A longitudinal analysis of T-cell epitope-coding regions of hepatitis C virus after liver transplantation
    Hugo R Rosen
    Department of Medicine, and Divisions of Gastroenterology Hepatology and Liver Transplantation, and Infectious Diseases, Portland Veterans Affairs Medical Center, Portland, Oregon 97207, USA
    Transplantation 74:209-16. 2002
    ..We hypothesized that amino acid substitutions within critical T-cell epitopes could lead to increased severity of HCV disease...
  45. ncbi request reprint Cytomegalovirus glycoprotein B groups in human immunodeficiency virus-infected patients with incident retinitis
    W Lawrence Drew
    Mount Zion Medical Center, University of California, San Francisco, CA 94115, USA
    J Infect Dis 186:114-7. 2002
    ..These rates were similar among case patients and control subjects and were similar by risk group. The CMV gB2 genotype is not a major determinant of retinitis pathogenicity but appears to be highly prevalent among HIV-infected patients...
  46. ncbi request reprint Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C
    Hugo R Rosen
    Division of Gastroenterology, Portland VAMC and Oregon Health Sciences University, 97207, USA
    Am J Gastroenterol 97:714-20. 2002
    ....
  47. pmc Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors
    Matthew J Gonzales
    Division of Infectious Diseases, Department of Medicine, Stanford University, CA, USA
    AIDS 17:791-9. 2003
    ..To characterize reverse transcriptase (RT) mutations by their association with extent of nucleoside RT inhibitor (NRTI) therapy. To identify mutational clusters in RT sequences from persons receiving multiple NRTI...

Research Grants13

  1. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2007
    ....
  2. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2003
    ....
  3. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 1999
    ..W. Lawrence Drew (UCSF) and from Dr. Alejo Erice (University of Minnesota). ..
  4. ANTIVIRAL DRUG RESISTANCE IN HUMAN CYTOMEGALOVIRUS
    Sunwen Chou; Fiscal Year: 2010
    ..Detailed understanding of the genetic mechanisms of resistance will improve the design of suitable new drug structures and antiviral targets. ..